We showed here that combination of KISIMA vaccination therapeutic protein vaccine with subcutaneous STINGa treatment profoundly impacts both quantity and quality of CD8 and CD4 T cells, which resulted in a prolonged control of tumor growth in both B16-OVA and TC-1 tumor models. The gene discussed is CD8A; the disease is neoplasm.